Elevance Health Inc.
HealthcareNYSE:ELV · New York Stock Exchange
+$2.93 today
Vol 0.93M · Avg 1.73M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$200.4B of revenue converted into $5.2B of net income for the selected period. Gross margin is 23.2% and net margin is 2.6%, showing how much revenue survives after costs and taxes. EPS is $23.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $199.1B +12.6% | $176.8B +3.2% | $171.3B +9.4% | $156.6B +13.0% | $138.6B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $148.2B +16.2% | $127.6B +2.6% | $124.3B +6.6% | $116.6B +13.6% | $102.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $50.9B +3.4% | $49.2B +4.8% | $47.0B +17.7% | $40.0B +11.0% | $36.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 25.6% -2.3pp | 27.9% +0.4pp | 27.4% +1.9pp | 25.5% -0.4pp | 26.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $0 | $0 | $0 | $0 | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $42.8B +6.0% | $40.4B +5.5% | $38.3B +21.5% | $31.5B +16.5% | $27.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.5B +11.0% | $1.4B -20.2% | $1.7B +4.2% | $1.7B +28.6% | $1.3B | $374.2M | $1.2B | $631.8M |
| EBITDA | $9.7B -7.9% | $10.5B -0.1% | $10.5B +3.6% | $10.1B +1.0% | $10.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 4.9% -1.1pp | 5.9% -0.2pp | 6.1% -0.3pp | 6.5% -0.8pp | 7.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.1B -8.7% | $8.9B +1.6% | $8.7B +3.5% | $8.5B -5.5% | $8.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 4.1% -1.0pp | 5.0% -0.1pp | 5.1% -0.3pp | 5.4% -1.1pp | 6.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.4B +18.3% | $1.2B +15.0% | $1.0B +21.0% | $851.0M +6.6% | $798.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.4B -42.5% | -$984.0M +4.5% | -$1.0B -21.0% | -$851.0M +16.7% | -$1.0B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $6.7B -15.1% | $7.9B +2.4% | $7.7B +1.5% | $7.6B -4.1% | $7.9B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 3.4% -1.1pp | 4.5% -0.0pp | 4.5% -0.4pp | 4.9% -0.9pp | 5.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.0B -45.7% | $1.9B +12.1% | $1.7B +0.7% | $1.7B -6.4% | $1.8B | $1.3B | -$1.6B | $745.2M |
| Net Income | $5.7B -5.3% | $6.0B -0.1% | $6.0B +1.6% | $5.9B -3.4% | $6.1B | $4.9B | $4.8B | $4.7B |
| Net Margin | 2.8% -0.5pp | 3.4% -0.1pp | 3.5% -0.3pp | 3.8% -0.6pp | 4.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $25 -2.4% | $26 +1.7% | $25 +3.3% | $25 -2.7% | $25 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $25 -2.2% | $26 +1.8% | $25 +3.9% | $24 -1.8% | $25 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $221.8M -4.8% | $232.9M -0.1% | $233.1M -2.9% | $240.0M -1.6% | $243.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $221.8M -4.8% | $232.9M -1.9% | $237.4M -2.2% | $242.8M -1.6% | $246.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.97B
GSK plc
NYSE:GSK
$106.56B
Cigna Corporation
NYSE:CI
$78.80B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.29B
Cencora, Inc.
NYSE:COR
$54.88B
Becton, Dickinson and Company
NYSE:BDX
$52.85B
Humana Inc.
NYSE:HUM
$45.43B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.09B
Zoetis Inc.
NYSE:ZTS
$33.64B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.58B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ELV generate?
Elevance Health Inc. (ELV) reported $199.13B of revenue in fiscal 2025.
Is ELV profitable?
Elevance Health Inc. (ELV) reported $5.66B of net income, with a net margin of 2.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.